Zentalis Pharmaceuticals, Inc.

Name: Zentalis Pharmaceuticals, Inc. standardized financial statements, quarterly
Creator: Listed

ZNTLNasdaqCIK 1725160HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q4 FY2025

Operating income−$44.4m, Q2 FY2026

Net income−$42.3m, Q2 FY2026

Zentalis Pharmaceuticals, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	0.0	0.0	40.6	0.0	0.0	26.9	0.0	0.0	0.0	0.0	not reported	not reported
Research and development	$m	46.8	51.6	49.6	48.4	36.8	33.0	27.2	27.6	23.0	29.5	28.7	35.2
Operating income	$m	(62.7)	(67.9)	(24.8)	(65.1)	(51.4)	(49.8)	(45.6)	(36.1)	(33.7)	(37.4)	(37.9)	(44.4)
Income tax	$m	0.0	(0.1)	0.1	0.3	(0.0)	(0.2)	0.0	0.0	0.0	0.4	0.1	0.1
Net income	$m	(55.5)	(60.9)	10.1	(88.3)	(40.2)	(47.5)	(48.3)	(26.9)	(26.7)	(35.2)	(35.4)	(42.3)
Diluted EPS	$ per share	(0.79)	not reported	0.14	(1.24)	(0.56)	not reported	(0.67)	(0.37)	(0.37)	not reported	(0.50)	(0.59)
Basic EPS	$ per share	(0.79)	not reported	0.14	(1.24)	(0.56)	not reported	(0.67)	(0.37)	(0.37)	not reported	(0.50)	(0.59)

Balance sheet

Cash and equivalents$24.8m, Q2 FY2026

Shareholders' equity$143.6m, Q2 FY2026

Zentalis Pharmaceuticals, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	111	28.0	37.6	37.0	41.3	33.9	41.9	37.6	39.1	36.0	31.9	24.8
Current assets	$m	528	497	504	440	400	386	343	312	288	253	218	181
Total assets	$m	586	552	557	492	451	430	384	352	327	289	253	215
Current liabilities	$m	58.9	69.4	54.8	66.7	54.9	52.7	49.4	39.0	37.2	36.6	35.2	37.6
Total liabilities	$m	104	114	98.7	109	96.3	93.2	88.6	77.2	74.4	72.8	70.4	71.7
Shareholders' equity	$m	482	437	459	383	354	337	295	274	253	216	183	144

Cash flow

Operating cash flow−$37.2m, Q2 FY2026

Capital expenditure$0, Q2 FY2026

Zentalis Pharmaceuticals, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(38.7)	(40.6)	(52.0)	(35.1)	(44.0)	(39.7)	(32.6)	(34.7)	(27.0)	(30.9)	(33.0)	(37.2)
Capital expenditure	$m	0.1	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Diluted shares (weighted)71.33m, Q2 FY2026

Zentalis Pharmaceuticals, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	56.8	59.3	60.8	70.6	71.2	71.0	71.1	71.7	72.0	72.1	70.3	71.3

Shares outstanding: 71.67m at Aug 3, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. Listed shows no prices and gives no investment advice.